{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:44:09Z","timestamp":1792086249778,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ctrv.2026.103146","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:54:56Z","timestamp":1777942496000},"page":"103146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Circulating tumor DNA for predicting recurrence and mortality in patients with resected Melanoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"147","author":[{"given":"Pedro C.","family":"Abrah\u00e3o Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Macambira","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Evangelista","family":"Ponte Conrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Romagnoli","family":"Buonopane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Diego","family":"Holanda Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel V.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick F.","family":"Saldanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctrv.2026.103146_b0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","article-title":"Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment","volume":"30","author":"Ahmed","year":"2020","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103146_b0010","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103146_b0015","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence\u2010based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA A Cancer J Clinicians. 2017;67(6):472-492. doi:10.3322\/caac.21409.","DOI":"10.3322\/caac.21409"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103146_b0020","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103146_b0025","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103146_b0030","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.ctrv.2026.103146_b0035","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103146_b0040","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103146_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100156","article-title":"The role of liquid biopsy as a catalyst for sustained progress in precision oncology - Perspective of the young committee of the international society of liquid biopsy","volume":"5","author":"Saldanha","year":"2024","journal-title":"J Liq Biopsy"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103146_b0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103146_b0055","first-page":"65","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin","volume":"22","author":"Pantel","year":"2025","journal-title":"Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103146_b0060","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103146_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012034","article-title":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D\/IV melanoma treated with adjuvant immunotherapy: CheckMate 915","volume":"13","author":"Long","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103146_b0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1470-2045(25)00139-1","volume":"26","author":"Syeda","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103146_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102788","article-title":"Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma","volume":"129","author":"De Simoni","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103146_b0080","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103146_b0085","article-title":"Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors","volume":"6","author":"Kasi","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103146_b0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103146_b0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103146_b0100","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103146_b0105","first-page":"344","article-title":"Confidence interval for the AUC of SROC curve and some related methods using bootstrap for meta-analysis of diagnostic accuracy studies","volume":"7","author":"Noma","year":"2021","journal-title":"Communications in Statistics: Case Studies, Data Analysis and Applications"},{"key":"10.1016\/j.ctrv.2026.103146_b0110","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21(1):111","author":"Liu","year":"2021","journal-title":"BMC Med Res Method"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103146_b0115","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103146_b0120","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103146_b0125","article-title":"Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma","volume":"43(16_suppl):9571\u20139571","author":"Ansstas","year":"2025","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103146_b0130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/CMR.0000000000000892","article-title":"Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma","volume":"33","author":"Brunsgaard","year":"2023","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2026.103146_b0135","article-title":"Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy","volume":"43(1):238","author":"Chan","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103146_b0140","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.34716","article-title":"Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients","volume":"129","author":"Eroglu","year":"2023","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103146_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103978","article-title":"Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients","volume":"9","author":"Genta","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103146_b0150","article-title":"Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III\/IV Melanoma patients by using Real-Time PCR","volume":"14(13):3053","author":"Giunta","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103146_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100357","article-title":"Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma","volume":"7","author":"Gouda","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103146_b0160","doi-asserted-by":"crossref","unstructured":"LaPelusa MB, Marcano D, Othus M, et al. Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404. JCO. 2024;42(16_suppl):9564-9564. doi:10.1200\/JCO.2024.42.16_suppl.9564.","DOI":"10.1200\/JCO.2024.42.16_suppl.9564"},{"key":"10.1016\/j.ctrv.2026.103146_b0165","article-title":"Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment","volume":"22(1):1074","author":"Marchisio","year":"2024","journal-title":"J Transl Med"},{"issue":"62","key":"10.1016\/j.ctrv.2026.103146_b0170","doi-asserted-by":"crossref","first-page":"105000","DOI":"10.18632\/oncotarget.21072","article-title":"Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E\/K mutation","volume":"8","author":"Momtaz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2026.103146_b0175","doi-asserted-by":"crossref","unstructured":"Arpi Palacios JE, Isaacs JM, Behera TR, et al. 618 Circulating tumor DNA as a predictive biomarker of recurrence for resected high-risk melanoma. In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2024:A712-A712. doi:10.1136\/jitc-2024-SITC2024.0618.","DOI":"10.1136\/jitc-2024-SITC2024.0618"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103146_b0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CMR.0000000000001041","article-title":"Circulating tumor DNA predicts tumor progression and poor survival in patients with stage III melanoma","volume":"35","author":"Palacios-Diaz","year":"2025","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103146_b0185","first-page":"5292","article-title":"Circulating Tumor DNA in High-Risk Stage II\/III Cutaneous Melanoma: a Feasibility Study. Ann Surg","volume":"32","author":"Rhodin","year":"2025","journal-title":"Oncol"},{"issue":"10427","key":"10.1016\/j.ctrv.2026.103146_b0190","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103146_b0195","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251412729","article-title":"Biomarker analysis of circulating tumor DNA in clinical stage III melanoma patients treated with neoadjuvant immunotherapy combined with targeted therapy","volume":"18","author":"Stoff","year":"2026","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103146_b0200","first-page":"1661","article-title":"From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol","volume":"12","author":"Rowe","year":"2018","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103146_b0205","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdz075","article-title":"Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103146_b0210","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Melanoma: Cutaneous. Version 1.2026. Accessed February 26, 2026. Published online 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1492."},{"issue":"30","key":"10.1016\/j.ctrv.2026.103146_b0215","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update","volume":"41","author":"Seth","year":"2023","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103146_b0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103146_b0225","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/cam4.1223","article-title":"High frequency of brain metastases after adjuvant therapy for high-risk melanoma","volume":"6","author":"Samlowski","year":"2017","journal-title":"Cancer Med"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103146_b0230","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1002\/cncr.34435","article-title":"Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma","volume":"128","author":"Johannet","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103146_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105109","article-title":"Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis","volume":"103","author":"Zheng","year":"2024","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103146_b0240","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-Adjuvant or Adjuvant-only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103146_b0245","article-title":"Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma","volume":"1(11):EVIDoa2200214","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103146_b0250","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s43018-026-01116-3","article-title":"A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection","volume":"7","author":"Zeng","year":"2026","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103146_b0255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:49:04Z","timestamp":1781059744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"alternative-id":["S0305737226000605"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103146","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA for predicting recurrence and mortality in patients with resected Melanoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103146"}}